Agenus, Inc. (NASDAQ:AGEN) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET
Company Participants
Zack Armen - Head, IR
Garo Armen - Chairman & CEO
Steven O'Day - CMO
Christine Klaskin - VP, Finance
Robin Taylor - CCO
Tom Harrison - Board of Directors
Conference Call Participants
Emily Bodnar - H.C. Wainright
Claire Duffy - Jefferies
Madison El-Saadi - B. Riley Financial
Madeline Stone - William Blair
Operator
Good morning and welcome to Agenus Second Quarter 2024 Results Conference Call and Webcast. All participants will be in a listen-only mode until the question-and-answer session. Please note, this event is being recorded. If anyone has any objections, you may disconnect at this time. [Operator Instructions]. Thank you.
I would now like to turn the call over to Zack Armen, Head of Investor Relations at Agenus. Zack, please go ahead.
Zack Armen
Thank you, Leonardo, and thank you all for joining us today. Today's call is being webcast and will be available on our website for replay. I'd like to remind you that this call will include forward-looking statements, including statements regarding our clinical development, regulatory and commercial plans and timelines, as well as timelines for data release and partnership opportunities among other updates. These statements are subjects to risks and uncertainties, and we refer you to our SEC filings available on our website for more details on these risks.
Joining me today are Dr. Garo Armen, Chairman and Chief Executive Officer; Dr. Steven O'Day, Chief Medical Officer; and Christine Klaskin, Vice President of Finance. Dr. Robin Taylor, Chief Commercial Officer will be participating in the Q&A session.
Now, I'd like to turn the call over to Garo to highlight our progress in the second quarter. Garo?
Garo Armen
Good morning, everyone and thank you for joining us on today's call.
On the merits of our circumstances and on matters within our control, with a strong emphasis on impacting patient lives, we have made significant progress in the development of botansilamab, which we call BOT, and bostilamab, which we call BAL. And these are for the treatment of colorectal cancer, even though the combination has been used for many other cancers.
Recently, Agenus disclosed top-line data from its global Phase II trial, evaluating the BOT/BAL combination in patients with relapsed refractory microsatellite stable, which is called MSS colorectal cancer. These patients constitute about 95% of the diagnosed colorectal cancer patients globally, and as you know, colorectal cancer has been on a significant rise as of late.